Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 701 - 750 out of 1,630

Document Document Title
WO/1999/064031A1
The present invention is directed to multibinding compounds which are $g(b)2-adrenergic receptor agonists and are therefore useful in the treatment and prevention of respiratory diseases such as asthma, bronchitis, and the like. They are...  
WO/1999/064039A1
Disclosed are multibinding compounds which are bradykinin antagonists. The multibinding compounds of this invention contain from 2 to 10 ligands covalently attached to one or more linkers. Each ligand is, independently of each other, a b...  
WO/1999/064044A1
Novel multibinding compounds are disclosed. The compounds of the invention comprise from 2-10 ligands covalently connected, each of said ligands being capable of binding to a 5-HT receptor, thereby modulating the biological processes/fun...  
WO/1999/063940A2
Disclosed are multibinding compounds which inhibit H?+¿/K?+¿-ATPase, an enzyme which is involved in the control of acid secretion in the stomach. The multibinding compounds of this invention containing from 2 to 10 ligands covalently a...  
WO/1999/063933A2
Disclosed are multibinding compounds which are agonists, partial agonists, inverse agonists, partial inverse agonist or antagonists of the GABA receptors, which are involved in neurological disorders. The multibinding compounds of this i...  
WO/1999/064045A1
Disclosed are multibinding compounds that bind cell membrane transporters and modulate their activity. The multibinding compounds contain from 2 to 10 ligands covalently attached to one or more linkers.  
WO/1999/064055A1
Disclosed are multibinding compounds which are agonists, partial agonists, inverse agonists or antagonists of the 5HT¿4? receptors, which are involved in gastrointestinal disorders. The multibinding compounds of this invention containin...  
WO/1999/063983A1
Disclosed are novel multi-binding compounds (agents) which bind to PPAR$g(g) receptors. The compounds of this invention comprise a plurality of ligands each of which can bind to such receptors thereby modulating the biological processes ...  
WO/1999/064048A1
Disclosed are multibinding compounds which inhibit the enzyme HIV reverse transcriptase, an enzyme which catalyzes the conversion of viral RNA to single stranded DNA. The multibinding compounds of this invention containing from 2 to 10 l...  
WO/1999/064054A1
Disclosed are multibinding compounds which inhibit topoisomerases which are essential enzymes in higher encaryotes for DNA replication and repair. The multibinding compounds of this invention containing from 2 to 10 ligands covalently at...  
WO/1999/064049A1
This invention relates to novel multibinding compounds (agents) that are antibacterial agents. The multibinding compounds of the invention comprise from 2-10 ligands covalently connected by a linker or linkers, wherein each of said ligan...  
WO/1999/064041A1
Disclosed are novel multi-binding compounds (agents) which bind to NMDA receptors. The compounds of this invention comprise a plurality of ligands each of which can bind to such receptors, thereby modulating the biological processes and/...  
WO/1999/064038A1
Novel multibinding compounds are disclosed. The compounds of the invention comprise from 2-10 ligands covalently connected, each of said ligands being capable of binding to an nAChR receptor, thereby modulating the biological processes/f...  
WO/1999/064034A1
The present invention is directed to multibinding compounds which are $g(b)2 adrenergic receptor agonists and are therefore useful in the treatment and prevention of respiratory diseases such as asthma, bronchitis, and the like. They are...  
WO/1999/064037A1
Novel multi-binding compounds are disclosed that modulate enzymatic processes. The compounds of the invention comprise from 2-10 ligands covalently connected, each of said ligands being capable of binding to an enzyme, enzyme substrate o...  
WO/1999/063993A1
Disclosed are multibinding compounds which are agonists, partial agonists, inverse agonists or antagonists of the D¿1? receptors, preferably, agonists of the D¿1? receptors, which are involved in neurological disorders. The multibindin...  
WO/1999/063999A1
This invention relates to novel multibinding compounds (agents) that are H1-histamine receptor antagonists and pharmaceutical compositions comprising such compounds. Accordingly, the multibinding compounds and pharmaceutical compositions...  
WO/1999/063984A1
The compounds of this invention comprise 2 - 10 ligands covalently connected, each of the ligands being capable of binding to a ligand binding site in an Na?+¿ channel, thereby modulating the biological activities thereof.  
WO/1999/063930A2
This invention relates to novel multibinding compounds that bind to angiotensin (AT) receptors and modulate their activity. The compounds of this invention comprise 2-10 AT receptor ligands covalently connected by a linker or linkers, wh...  
WO/1999/064043A1
Disclosed are multibinding compounds which are muscarinic receptor antagonists. The multibinding compounds of this invention containing from 2 to 10 ligands covalently attached to one or more linkers. Each ligand is, independently of eac...  
WO/1999/064053A1
The present invention is directed to multibinding compounds which are $g(b)3-adrenergic receptor agonists and are therefore useful in the treatment and prevention of metabolic disorders such as obesity, diabetes, and the like.  
WO/1999/064032A1
Disclosed are methods for synthesizing large collections of diverse multimeric compounds as well as iterative processes for evaluating key molecular constraints imparting multibinding properties to multimeric compounds. Also disclosed ar...  
WO/1999/064033A1
This invention relates to novel multibinding compounds that bind to the enzyme phosphodiesterase V (PDE V) and modulate its activity. The compounds of this invention comprise 2-10 PDE V modulator (particularly inhibitor) ligands covalent...  
WO/1999/063936A2
Novel multi-binding compounds (agents) which bind endothelin receptors are used to treat disorders affecting the cardiovascular, renal, endocrine and nervous systems in mammals that are mediated by the endothelin receptors, such as conge...  
WO/1999/063988A1
Disclosed are multibinding compounds which inhibit nitric oxide synthases (NOSs), enzymes which form nitric oxide and L-citrulline from L-arginine. The multibinding compounds of this invention contain from 2 to 10 ligands covalently atta...  
WO/1999/064035A1
Disclosed are multibinding compounds which are $g(b)2-adrenergic receptor agonists and are useful in the treatment and prevention of respiratory diseases such as asthma, bronchitis. They are also useful in the treatment of nervous system...  
WO/1999/063937A2
Disclosed are multibinding compounds which include macrolide antibiotics, aminoglycosides, lincosamides, oxazolidinones, streptogramins, tetracycline and/or other compounds which bind to bacterial ribosomal RNA and/or to one or more prot...  
WO/1999/062563A2
Breast and/or prostate cancer is diagnosed and/or treated with a radiolabeled peptide or peptidomimetic that binds to GRP (Gastrin Releasing Peptide) receptors.  
WO/1999/059560A1
The invention provides methods and compounds for modulating the number of GLUT4 sorting vesicle resident molecules on the surface of a cell. The invention also provides methods of treating NIDDM in a subject. Methods of evaluating compou...  
WO/1999/055900A2
The invention provides gcp polypeptides and polynucleotides encoding gcp polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing gcp polypeptides to screen for antibacte...  
WO/1999/050664A1
The invention provides a method based upon the two hybrid system for examining the interactions of nuclear receptors. The invention is additionally directed to compositions for use in the assay and a method of identifying ligands of nucl...  
WO/1999/050657A1
Signaling pathways dependent on members of the corticotropin releasing factor (CRF) gene family exert pleiotropic effects within both the brain and peripheral tissues. Two biochemically and pharmacologically distinct corticotropin releas...  
WO/1999/047253A1
The invention refers to a new process for preparing coated particles and hollow shells by coating colloidal particles with alternating layers of oppositely charged nanoparticles and polyelectrolytes and optionally removing the colloidal ...  
WO1999023236A9
Disclosed is a method of producing random polynucleotides by introducing two or more related polynucleotides into a suitable host cell such that a hybrid polynucleotide is generated by recombination and reductive reassortment. Also provi...  
WO/1999/041612A1
The present invention provides methods and compositions for screening, diagnosis and prognosis of hepatoma, for monitoring the effectiveness of hepatoma treatment, and for drug development. Hepatoma-Diagnostic Features (HFs), detectable ...  
WO1998033901A9
The invention concerns gene banks and combinatorial derivatives thereof, prepared using phagemid- or phage-display in combination with type IIS restriction enzymes and cosmid packaging; their use for the isolation of ligands, including e...  
WO1998033901A3
The invention concerns gene banks and combinatorial derivatives thereof, prepared using phagemid- or phage-display in combination with type IIS restriction enzymes and cosmid packaging; their use for the isolation of ligands, including e...  
WO1999010527A3
The invention relates to a method for isolating anionic organic substances from aqueous systems using polymer nanoparticles with cationic pH-sensitive surface groups. Extraction can be carried out directly from diluted solutions, biologi...  
WO/1999/023236A1
Disclosed is a method of producing random polynucleotides by introducing two or more related polynucleotides into a suitable host cell such that a hybrid polynucleotide is generated by recombination and reductive reassortment. Also provi...  
WO/1999/012959A1
The present invention relates to the field of carbohydrate crosslinked glycoprotein crystals. Advantageously, such crosslinked glycoprotein crystals display stability to harsh environmental conditions, while maintaining the structural an...  
WO/1999/011283A1
The present invention provides for a method for treating a subject suffering from a condition associated with an extracellular zinc sphingomyelinase activity which comprises administering to the subject an amount of a zinc sphingomyelina...  
WO/1999/010527A2
The invention relates to a method for isolating anionic organic substances from aqueous systems using polymer nanoparticles with cationic pH-sensitive surface groups. Extraction can be carried out directly from diluted solutions, biologi...  
WO/1999/001940A1
Using a whole byte to represent a monomer in a biological sequence is not the most efficient means of permanent storage. The invention relates to the compression of biological sequence data for electronic storage by utilising a sub-byte ...  
WO/1998/058967A1
This invention describes self assembled monolayers (SAMs) manufactured by imprinting reactive peptides onto solid supports. The invention further relates to methods of preparing and using these improved SAMs.  
WO/1998/033901A2
The invention concerns gene banks and combinatorial derivatives thereof, prepared using phagemid- or phage-display in combination with type IIS restriction enzymes and cosmid packaging; their use for the isolation of ligands, including e...  
WO/1998/028434A1
Oligopeptides are ligated to form ligation peptide products. In the first step, two starting oligopeptides are ligated to form an intermediate having an aminothioester linkage. In the second step, the aminothioester linkage undergoes a r...  
WO/1998/020023A1
The present invention relates generally to therapeutic and diagnostic agents. More particularly, the present invention provides therapeutic molecules capable of modulating signal transduction such as but not limited to cytokine-mediated ...  
WO/1998/011129A1
This invention is directed to novel (N-substituted)indole ICE/ced-3-inhibitor compounds. The invention is also directed to pharmaceutical compositions of such indole compounds, plus the use of such compositions in the treatment of patien...  
WO/1998/011204A1
Purified and recombinant proteins TPC2 and TPC3 and recombinant or synthetic oligonucleotides corresponding to those proteins or fragments thereof can be used to detect regulators of telomere length and telomerase activity in mammalian c...  
WO1997046259A3
The present invention relates particularly to neoplastic cells targeted chimeric toxins comprising of cell targeting moieties and cell killing moieties for recognizing and for destroying the neoplastic cells, wherein the cell targeting m...  

Matches 701 - 750 out of 1,630